Pfizer and BioNTech Doze First Participants in the U.S. As Part of Global COVID-19 MRNA Vaccine Development Program

NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of …

Read MorePfizer and BioNTech Doze First Participants in the U.S. As Part of Global COVID-19 MRNA Vaccine Development Program